New patients treated for PNE with desmopressin should only be prescribed an oral formulation.
PNE新患者仅限用去氨加压素的口服剂型。
Objective To study the adverse drug reaction (ADR) of desmopressin (DDAVP) in clinical application, improving clinical medication.
目的了解和分析去氨加压素在临床应用中不良反应，促进临床合理用药。
Prebiopsy desmopressin administration decreases the risk of bleeding and hematoma size in patients undergoing percutaneous kidney biopsy without a cost increase.
在经皮肾穿刺患者中，穿刺前给予去氨加压素减少出血风险、减少血肿大小，而不增加住院费用。
Although this was not a controlled trial, they concluded that desmopressin is "safe and effective in the treatment of severe nocturia in patients 65 years old and older."
尽管这不是一个设有对照的试验，但研究者断定去氨加压素能安全有效地治疗65岁及65岁以上患者的重度夜尿症。
All patients using intranasal formulations of desmopressin for treatment of PNE should be reassessed to determine their need for continued treatment and to discuss other options.
要对所有正在使用鼻腔用去氨加压素的患者进行重新评估，来决定是继续用药还是选择别的治疗方案。
The finding helps physiologists understand why about 30% of children who suffer from bedwetting (nocturnal enuresis) do not respond to desmopressin, a drug that successfully treats the other 70%.
上述结果帮助了生理学家理解了为什么去氨加压素对约30%的尿床儿童(又称夜间遗尿症)不起作用，而这个药物对其他70%的尿床儿童却成功治疗。
The finding helps physiologists understand why about 30% of children who suffer from bedwetting (nocturnal enuresis) do not respond to desmopressin, a drug that successfully treats the other 70%.
上述结果帮助了生理学家理解了为什么去氨加压素对约30%的尿床儿童(又称夜间遗尿症)不起作用，而这个药物对其他70%的尿床儿童却成功治疗。
应用推荐